Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 43.78Mã«éããŠããŸãã
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 43.78Mã§ãã
å²é«
åç€Ÿã®ææ°ã®PEã¯-0.07ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé«å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯876.37Kæ ªã§ãåååææ¯ã§70.31%æžå°ããŠããŸãã
ãžã§ãŒã ãºã»ã·ã¢ã³ãºãä¿æ
ã¹ã¿ãŒæè³å®¶ãžã§ãŒã ãºã»ã·ã¢ã³ãºã¯æ¬éæã14.17Kæ ªä¿æããŠããŸãã
åžå ޿޻åãæŽ»çº
å瀟ãžã®æè³å®¶ã®é¢å¿ãé«ãŸã£ãŠããã20æ¥éã®å£²è²·å転çã¯0.85ã§ãã